Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
Clinical trial NCT03388632 · COMPLETED
Trial details
- NCT number
- NCT03388632
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-05
- Primary completion
- 2024-11-27
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.